COVAX: CEPI's response to COVID-19 About us Get involved Research COVAX Marketplace News & stories Careers Contact New vaccines for a safer world The Coalition for Epidemic Preparedness Innovations (CEPI) is a global partnership launched in 2017 to develop vaccines to stop future epidemics. FIND OUT MORE CEPI’s $3.5 billion plan to tackle epidemic and pandemic infectious diseases Learn more about CEPI’s $3.5 billion plan to push the bounds of vaccine R&D to substantially reduce global epidemic and pandemic risk. LEARN MORE Latest news VIEW ALL CEPI Statement: Emergence of a new SARS-CoV-2 variant, B.1.1.529 Statement from CEPI CEO, Dr Richard Hatchett. COVID-19 26 Nov 2021 CEPI funds Aga Khan University-led consortium to conduct mix-and-match trial of COVID-19 vaccines in Pakistan New collaboration will assess the safety and immunogenicity of heterologous – or ‘mix-and-match’ - combinations of three COVID-19 vaccines currently being deployed in Pakistan. COVID-19 23 Nov 2021 World's largest COVID-19 vaccine testing network to assess vaccines against other epidemic and pandemic threats Set up and funded by CEPI, the network aims to more rapidly, efficiently, and accurately identify the most promising vaccine candidates with the greatest potential to advance to late-stage clinical trials and regulatory review. End Pandemics We want to create a world in which epidemics are no longer a threat to humanity. CEPI wants to galvanise the development of new vaccines against diseases we know could cause the next devastating epidemic. OUR APPROACH $570bn The estimated annual global cost of moderately severe to severe pandemics Eleven The number of diseases WHO identified as public health risks due to epidemic potential and lack of biomedical countermeasures $2.8bn The minimum average cost for progressing one vaccine against each of WHO’s 11 priority epidemic infectious diseases Epidemic diseases affect us all. They do not respect borders. CEPI (pronounced 'seppy') aims to accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks. WHO WE ARE Ahmedabad, India (Paula Bronstein/Getty Images Reportage) Get involved Invest Become a partner Our work Our portfolio Jobs at CEPI Careers at CEPI Latest openings Contact Us Contact Privacy ABOUT US Why we exist Mission Approach Who we are Overview Leadership Board Investors & Partners Scientific Advisory Committee Joint Coordination Group Antiracism statement Anti-Slavery Statement Governance Articles of association Board Meeting Summaries Board of Directors' report, annual accounts and Auditor's statement Business Plan CEPI Policies Equitable Access Financial Internal policies Investors Council Joint Coordination Group Members Meetings Other Guidance for Awardees Scientific Advisory Committee Strategy & Progress Terms of reference GET INVOLVED Support CEPI Invest in CEPI Progress Work with CEPI Work at CEPI Follow our work Calls for Proposals RESEARCH & DEVELOPMENT Our portfolio Platform Technology Priority diseases MERS Lassa Nipah Disease X Rift Valley fever Chikungunya Ebola Vaccine science Biological Standards, Assays & Animal Models Collect vaccine data Researching emerging infectious diseases INFO & ACTION News & stories Outbreaks Careers Contact Social LinkedIn Twitter Legal Terms of use Privacy policy Procurement tenders Reporting Concern ©2021 CEPI. All rights reserved